4.09% Less Abbvie Inc (NYSE:ABBV) Shares Shorted

April 17, 2018 - By Mark Mitchell

AbbVie Inc. (NYSE:ABBV) Corporate Logo

Big Money Sentiment decreased to 0.8 in 2017 Q4. It has change of 0.05, from 2017Q3’s 0.85. The ratio fall due to AbbVie Inc. positioning: 42 sold and 695 reduced. 139 funds bought holdings and 448 increased holdings. Investors holded 1.06 billion in 2017Q3 but now own 1.06 billion shares or 0.35% more.
The Ontario – Canada-based Ontario Teachers Pension Plan Board has invested 0.08% in AbbVie Inc. (NYSE:ABBV). Westover Capital Advisors Llc reported 22,714 shs. Parsons Cap Mgmt Inc Ri invested in 80,138 shs. The Connecticut-based Cubist Systematic Strategies Ltd has invested 0.22% in AbbVie Inc. (NYSE:ABBV). Goodman Fincl Corp accumulated 700 shs or 0.03% of the stock. Profund Lc reported 608,615 shs. Marshwinds Advisory holds 32,358 shs. Numeric Ltd Limited Liability Company has invested 0.66% in AbbVie Inc. (NYSE:ABBV). Ar Asset Mngmt Inc owns 12,200 shs for 0.45% of their capital. Proshare Advsrs Ltd Company owns 1.02M shs or 0.68% of their US capital. 15,401 were reported by Intrust Bancorporation Na. Private Ocean Lc holds 0.07% of its capital in AbbVie Inc. (NYSE:ABBV) for 1,271 shs. Mogy Joel R Investment Counsel stated it has 71,383 shs or 1.08% of all its holdings. Moreover, Lynch Assocs In has 2.27% invested in AbbVie Inc. (NYSE:ABBV). Virginia-based Alexandria Ltd Llc has invested 0.11% in AbbVie Inc. (NYSE:ABBV).

AbbVie Inc. had 12 sales and 0 buys since October 30, 2017. This’s net activity of $49.35 million. GONZALEZ RICHARD A sold $976,084 worth of stock. Michael Robert A. sold 4,294 shs worth $512,853. On Monday, December 18 $8.57M worth of AbbVie Inc. (NYSE:ABBV) was sold by RICHMOND TIMOTHY J.. 145,510 shs were sold by Schumacher Laura J, worth $14.07M on Thursday, December 14. On Wednesday, February 28 SEVERINO MICHAEL sold $311,684 worth of AbbVie Inc. (NYSE:ABBV) or 2,643 shs. Shares for $157,458 were sold by SALEKI-GERHARDT AZITA on Wednesday, February 28.

Abbvie Inc (NYSE:ABBV) had a decrease of its shares shorted by 4.09%. In April was announced ABBV’s total 15.25 million shares shorted by FINRA. Previously was reported down change of 4.09% from 15.90M shares. Former ABBV’s position will need 1 days to recover. It has 11.13M average volume.

The stock increased 0.84% or $0.77 during the last trading session, reaching $92.6.Currently AbbVie Inc. is uptrending after 39.20% change in last April 17, 2017. ABBV has 3.92 million shares volume. The stock outperformed the S&P 500 by 27.65%.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide.The firm is worth $146.93 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.28.06 is the P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Total analysts of 13 have positions in AbbVie (NYSE:ABBV) as follows: 6 rated it a “Buy”, 1 with “Sell” and 6 with “Hold”. The positive are 46%. The firm has $15700 highest while $80 is the lowest [Target]. The average target $123.91 is 33.81% above the last ($92.6) price. Since October 30, 2017 according to StockzIntelligence Inc AbbVie has 25 analyst reports. On Thursday, March 22 the firm earned “Buy” rating by SunTrust. The stock rating was maintained by Barclays Capital with “Equal-Weight” on Thursday, April 5. The company rating was maintained by Morgan Stanley on Tuesday, January 30. On Monday, October 30 the stock has “Outperform” rating by Leerink Swann. On Monday, November 20 the firm earned “Buy” rating by Cowen & Co. In Thursday, March 22 report Leerink Swann maintained the stock with “Hold” rating. On Thursday, November 16 the firm has “Market Perform” rating by BMO Capital Markets given. On Friday, January 26 the rating was maintained by Cowen & Co with “Buy”. The stock rating was maintained by Credit Suisse with “Hold” on Monday, January 29. On Tuesday, April 10 the company was maintained by Piper Jaffray.

AbbVie Inc. (NYSE:ABBV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.